New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapes
World medicine November 11,2023
3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapes
World medicine November 11,2023
Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhDMinimal residual disease (MRD) negativity sustainedfor 6 months or longer with ciltacabtagene autoleucel (cilta-cel; Carvykti) prolongedduration of response (DOR) and progre
World medicine November 09,2023
Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhDMinimal residual disease (MRD) negativity sustainedfor 6 months or longer with ciltacabtagene autoleucel (cilta-cel; Carvykti) prolongedduration of response (DOR) and progre
World medicine November 09,2023
Lamanna Details Evolution of CLL Treatment Following Resistance

Lamanna Details Evolution of CLL Treatment Following Resistance

Nicole Lamanna, MDFollowing progression, sequencing noncovalent vs covalent BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL) is key, and data support treating patien
World medicine November 09,2023
Lamanna Details Evolution of CLL Treatment Following Resistance

Lamanna Details Evolution of CLL Treatment Following Resistance

Nicole Lamanna, MDFollowing progression, sequencing noncovalent vs covalent BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL) is key, and data support treating patien
World medicine November 09,2023
STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

Rahul Aggarwal, MDThe six transmembrane epithelial antigen of the prostate 1 (STEAP1) has gained traction as a potential therapeutic target in recent years in multiple cancer types due to its overexpr
World medicine November 09,2023
STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

Rahul Aggarwal, MDThe six transmembrane epithelial antigen of the prostate 1 (STEAP1) has gained traction as a potential therapeutic target in recent years in multiple cancer types due to its overexpr
World medicine November 09,2023
Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer, according to a study published ineBioMedicine&
World medicine November 09,2023
Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer, according to a study published ineBioMedicine&
World medicine November 09,2023
Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

Lisa M. Carey, MD, ScM, FASCOResponse-guided therapies for patients with HER2-positive disease continue to evolve as upcoming clinical trials aim to provide answers on optimal treatments, according to
World medicine November 09,2023
Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

Lisa M. Carey, MD, ScM, FASCOResponse-guided therapies for patients with HER2-positive disease continue to evolve as upcoming clinical trials aim to provide answers on optimal treatments, according to
World medicine November 09,2023
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Lieping Chen, MD, PhDAlthough the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the ef
World medicine November 09,2023
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Lieping Chen, MD, PhDAlthough the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the ef
World medicine November 09,2023
SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

Timothy Yap, MBBS, PhD, FRCPWhen the fully human IgG4 monoclonal antibody SRK-181 was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metas
World medicine November 09,2023
SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

Timothy Yap, MBBS, PhD, FRCPWhen the fully human IgG4 monoclonal antibody SRK-181 was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metas
World medicine November 09,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com